Journal of International Psychiatry

Nearly one-third of patients with schizophrenia show poor response to first-line antipsychotic treatments and this is termed treatment-resistant schizophrenia. Studies have shown that the neurochemical abnormalities in treatment-resistant schizophrenia may not be associated with dopaminergic, but with glutamatergic. In recent, more and more studies focus on the glutamatergic neurometabolites abnormalities in brain of patients with treatment-resistant schizophrenia. Studies of glutamatergic glutamatergic neurometabolites levels in diverse brain regions, mainly concentrate on anterior cingulate cortex, dorsolateral prefrontal cortex and caudate nucleus. This article mainly introduces the research progress on glutamatergic neurometabolites levels in brain of patients with treatment-resistant schizophrenia.

treatment-resistant schizophrenia; glutamatergic; neurometabolites